Deutsche Bank AG Reduces Position in 22nd Century Group Inc (XXII)

Deutsche Bank AG lowered its stake in shares of 22nd Century Group Inc (NYSEAMERICAN:XXII) by 34.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 151,837 shares of the biotechnology company’s stock after selling 81,007 shares during the quarter. Deutsche Bank AG’s holdings in 22nd Century Group were worth $377,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in XXII. Cetera Advisors LLC grew its holdings in shares of 22nd Century Group by 16.9% in the 4th quarter. Cetera Advisors LLC now owns 27,615 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 4,000 shares during the last quarter. Advisor Group Inc. lifted its holdings in 22nd Century Group by 9.4% during the 4th quarter. Advisor Group Inc. now owns 61,340 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 5,250 shares during the last quarter. LPL Financial LLC lifted its holdings in 22nd Century Group by 49.1% during the 4th quarter. LPL Financial LLC now owns 26,800 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 8,820 shares during the last quarter. SG Americas Securities LLC lifted its holdings in 22nd Century Group by 56.5% during the 4th quarter. SG Americas Securities LLC now owns 26,784 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 9,672 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its holdings in 22nd Century Group by 60.8% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 26,040 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 9,842 shares during the last quarter.

Shares of 22nd Century Group stock opened at $2.14 on Friday. 22nd Century Group Inc has a 1 year low of $1.58 and a 1 year high of $3.29.

22nd Century Group (NYSEAMERICAN:XXII) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.02) earnings per share for the quarter. The firm had revenue of $6.29 million during the quarter.

Several brokerages have issued reports on XXII. Chardan Capital reaffirmed a “buy” rating and set a $11.50 price target on shares of 22nd Century Group in a report on Friday, March 15th. TheStreet downgraded 22nd Century Group from a “c-” rating to a “d+” rating in a report on Friday, March 29th.

TRADEMARK VIOLATION WARNING: “Deutsche Bank AG Reduces Position in 22nd Century Group Inc (XXII)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2019/05/25/deutsche-bank-ag-reduces-position-in-22nd-century-group-inc-xxii.html.

22nd Century Group Profile

22nd Century Group, Inc, a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies.

Featured Story: Why is the price-sales ratio important?

Want to see what other hedge funds are holding XXII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 22nd Century Group Inc (NYSEAMERICAN:XXII).

Institutional Ownership by Quarter for 22nd Century Group (NYSEAMERICAN:XXII)

Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit